It is included as a subtype of age-related macular degeneration (AMD) with a substantially shared genetic susceptibility with typical AMD5 and has been successfully treated using anti-vascular endothelial growth factor (anti-VEGF) drugs— both in clinical trials6–9 and in real-world clinical settings10–12. This evidence concerns the gene VEGFA and age-related macular degeneration.